GBG Research at ESMO Virtual Meeting 2020


Data of several GBG studies was presented at the upcoming ESMO Virtual Meeting 2020, which took place from 19 to 21 September 2020.

ePoster #248TiP Date: 17.09.2020
Speaker: Sibylle Loibl (Neu-Isenburg, Germany)
GeparDouze study (GBG 96): A randomized, double-blind, phase III trial of neoadjuvant chemotherapy (NACT) with atezolizumab/placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant continuation of atezolizumab/placebo (GeparDouze)
Loibl S, Rastogi P, Seiler S, et al.
Poster download

ePoster #176P Date: 17.09.2020
Speaker: Jan Hauke (Köln, Germany)
GeparOLA study (GBG 90): Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332)
Hauke J, Ernst C, Fasching PA, et al.
Poster download

Mini oral presentation #168MO Date: 18.09.2020 Session: Mini Oral - Breast cancer, early stage
Chairs: Hope S. Rugo (San Francisco, CA, United States of America), Prudence Francis (Melbourne, VIC, Australia), Shaheenah Dawood (Dubai, United Arab Emirates)
Speaker: Theresa Link (Dresden, Germany)
GeparX study (GBG 88): Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status
Link T, Blohmer J-U, Just M, et al.
Presentation download

Oral presentation #160O Date: 20.09.2020 Time: 12:54 - 13:06 Room: Channel 3
Chairs: Javier Cortés (Barcelona, Spain), Sherko Kümmel (Essen, Germany)
Speaker: Andreas Schneeweiss (Heidelberg, Germany)
GeparOcto study (GBG 84): Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC)
Schneeweiss A, Möbus V, Tesch H, et al.
Presentation dowload

External Presentation #LBA12 Date: 20.09.2020 Time: 13:26 - 13:38 Room: Channel 3
Chairs: Javier Cortés (Barcelona, Spain), Sherko Kümmel (Essen, Germany)
Speaker: Erica L. Mayer (Boston, United States of America)
PALLAS study (GBG 87): A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer

ESMO 2020


GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd